RINGOES, NJ, September 08, 2025 /24-7PressRelease/ -- Erin D. Henitz has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Ms. Henitz is a recognized leader in oncology and operations leadership, currently serving as Vice President and Global Head of Translational and Quantitative Science Data Management and Clinical Biomarker Operations at Genmab. Since assuming her role in 2024, Ms. Henitz has led a cross-functional team responsible for advancing programs from early phase one first in human trials into late-stage clinical development. She drives strategic planning discussions, leads governance and portfolio meetings, and ensures operational readiness for clinical execution. She collaborates closely with cross-departmental stakeholders and plays a pivotal role in budget development, resource prioritization, and aligning program investments with Genmab's broader scientific and business objectives.

Before assuming her current role, Ms. Henitz held a series of impactful leadership positions at Genmab between 2018 and 2024. Most recently, she served for two years as Senior Director and Global Head of Precision Medicine Operations and Diagnostics, where she was instrumental in driving forward key precision medicine initiatives. Prior to that, she led the Biomarker Operations and Trial Management group for solid tumors as Senior Director, following her initial appointment at Genmab as Director of Biomarker Operations.

Ms. Henitz's career also includes notable contributions to The Janssen Pharmaceutical Companies of Johnson & Johnson. From 2017 to 2018, she served as Director of Oncology and Translational Research Operations Lead. Under her leadership, the team successfully built a unified dashboard that integrated multiple data sources, providing real-time visibility into clinical biosample status and location for both her team and the broader organization.

Earlier in her tenure at Janssen, Ms. Henitz held roles as Associate Director of Oncology Translational Research and Manager of Oncology Biomarker Operations. She began her career at Bristol-Myers Squibb, where she served as a Sample Bank Coordinator from 2002 to 2005.

Ms. Henitz's academic background laid the groundwork for her professional achievements. She earned a Master of Science in Biotechnology Management from the University of Maryland in 2013, following a Bachelor of Science in Biology from Stockton University in 2003. Leveraging the expertise gained through her education, she has contributed to the approval of at least eight novel therapeutics, an accomplishment she regards with great pride, particularly in witnessing the meaningful impact these treatments have had on the lives of patients living with cancer.

Ms. Henitz's dedication to innovation was honored with an Innovation Award from Johnson & Johnson. Outside of her professional achievements, she devotes much of her time to civic engagement, having served for two years as President and Director of a township recreational soccer league. Whether in her personal or professional life, she credits her success to a natural ability to connect with others, an asset that has enabled her to navigate complex interpersonal dynamics and foster strong, collaborative relationships.

A proud mother of three, Ms. Henitz treasures time spent with her family and enjoys cooking as a favorite pastime. Her career has been profoundly shaped by her upbringing in a family of researchers, nurses, and scientists. Inspired by her mother's leadership as the head of a Neonatal Intensive Care Unit, she was raised in an environment defined by compassion, discipline, and a deep commitment to helping others.

Looking ahead, Ms. Henitz remains focused on contributing to an industry that brings innovative solutions to complex diseases. She believes her diverse experience across both large pharmaceutical organizations and agile biotech firms uniquely positions her for continued impact. If she were to transition from Genmab, it would be in pursuit of a leadership role at a promising start-up, where her strategic insight and operational expertise could drive transformative growth.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #